Next Article in Journal
Recent Developments in the Biological Activities, Bioproduction, and Applications of Pseudomonas spp. Phenazines
Next Article in Special Issue
The Anti-Aggregative Potential of Resolvin E1 on Human Platelets
Previous Article in Journal
Recent Advances in the Synthesis of Cyclic Sulfoximines via C–H Bond Activation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 3
10.3390/molecules28031369
Review Report
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update

Molecules 2023, 28(3), 1369; https://doi.org/10.3390/molecules28031369
by Collin Vandemark, Jimmy Nguyen and Zhi-Qing Zhao *
Reviewer 1:
Martina Smolić
Reviewer 2:
Viacheslav Nikolaev
Molecules 2023, 28(3), 1369; https://doi.org/10.3390/molecules28031369
Submission received: 28 November 2022 / Revised: 28 January 2023 / Accepted: 29 January 2023 / Published: 1 February 2023
(This article belongs to the Special Issue Novel Strategies for the Prevention and Treatment of Cardiovascular Diseases: New Horizons from Pharmaceuticals to Nutraceuticals)

Round 1

Reviewer 1 Report

The MS is well written, structured and the figures are understandable. Watch for typos, spaces, and consistency in spelling abbreviations, e.g., ACh or Ach? Section 2 Cite in the text some studies on liraglutide and the dual effect on the AT1R and AT2R. Briefly mention some other in vivo and in vitro studies on semaglutide, dulaglutide, and albiglutide in cardiovascular disease and compare them with studies on liraglutide.

Author Response

Responses to Reviewer #1

The MS is well written, structured and the figures are understandable. Watch for typos, spaces, 

and consistency in spelling abbreviations, e.g., ACh or Ach? Section 2 Cite in the text some studies on liraglutide and the dual effect on the AT1R and AT2R. Briefly mention some other in vivo and in vitro studies on semaglutide, dulaglutide, and albiglutide in cardiovascular disease and

compare them with studies on liraglutide.

Responses:  Spelling abbreviations have been carefully checked. Potential application of other GLP-1 receptor agonists as mentioned above in cardioprotection have been addressed (please see lines in text 525-529), thank you!

Reviewer 2 Report

The review is well written and includes primarily a summary of their own work, however it is clearly stated in the review when they are referring to their own work and results which helps to minimise any bias in the presentation or interpretation of the literature summary. Minor comments below, 

  • The authors may consider adding one small paragraph comparing other co-treatment with other insulin sensitising drugs such as Dapagliflozin or empagliflozin. How do these compare to liraglutide considering that the general theme of the review is that liraglutide has positive effects that are independent of improved glycaemic control.
  • Line 23. Correct to co-exists instead of co-existed
  • Line 135. Correct to enhancement instead of enchantment
  • Line 233. Correct font change
  • Line 388. Correct font change.
  • Line 456. Correct font change.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Back to TopTop